| Cardiostimulant effects of urotensin-II in human heart in vitro. | |
| | |
MedLine Citation:
|
PMID: 11156554 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The effects of the recently identified human peptide urotensin-II (hU-II) were investigated on human cardiac muscle contractility and coronary artery tone. In right atrial trabeculae from non-failing hearts, hU-II caused a concentration-dependent increase in contractile force (pEC(50)=9.5+/-0.1; E(max)=31.3+/-4.8% compared to 9.25 mM Ca(2+); n=9) with no change in contraction duration. In right ventricular trabeculae from explanted hearts, 20 nM hU-II caused a small increase in contractile force (7.8+/-1.4% compared to 9.25 mM Ca(2+); n=3/6 tissues from 2 out of 4 patients). The peptide caused arrhythmic contractions in 3/26 right atrial trabeculae from 3/9 patients in an experimental model of arrhythmia and therefore has less potential to cause arrhythmias than ET-1. hU-II (20 nM) increased tone (17.9% of the response to 90 mM KCI) in 7/7 tissues from 1 patient, with no response detected in 8/8 tissues from 2 patients. hU-II is a potent cardiac stimulant with low efficacy. |
| | |
Authors:
|
F D Russell; P Molenaar; D M O'Brien |
Related Documents
:
|
10485594 - Hemofiltrate from patients with severe sepsis and depressed left ventricular contractil... 2544724 - Nonsteroidal cardiotonics. 2. the inotropic activity of linear, tricyclic 5-6-5 fused h... 11786524 - Cardiac-specific overexpression of inducible nitric oxide synthase does not result in s... 11907014 - Progressive cardiac hypertrophy and dysfunction in atrial natriuretic peptide receptor ... 6740184 - A method for the study of the dynamics of atherosclerotic involvement of human coronary... 14615024 - Predicting the future of human gene therapy for cardiovascular diseases: what will the ... |
Publication Detail:
|
Type: In Vitro; Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: British journal of pharmacology Volume: 132 ISSN: 0007-1188 ISO Abbreviation: Br. J. Pharmacol. Publication Date: 2001 Jan |
Date Detail:
|
Created Date: 2001-01-26 Completed Date: 2001-05-24 Revised Date: 2009-11-18 |
Medline Journal Info:
|
Nlm Unique ID: 7502536 Medline TA: Br J Pharmacol Country: England |
Other Details:
|
Languages: eng Pagination: 5-9 Citation Subset: IM |
Affiliation:
|
The National Heart Foundation and Prince Charles Hospital Foundation Cardiovascular Research Centre, Department of Medicine, The Prince Charles Hospital, Chermside, Queensland 4032, Australia. russell@medicine.uq.edu.au |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Arrhythmias, Cardiac
/
chemically induced,
physiopathology Cardiotonic Agents / pharmacology* Coronary Vessels / drug effects Heart / drug effects* Heart Atria / drug effects Heart Ventricles / drug effects Humans Muscle Tonus / drug effects Muscle, Smooth, Vascular / drug effects Myocardial Contraction / drug effects Urotensins / pharmacology* |
| Chemical | |
Reg. No./Substance:
|
0/Cardiotonic Agents; 0/Urotensins; 9047-55-6/urotensin II |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Pregabalin may represent a novel class of anxiolytic agents with a broad spectrum of activity.
Next Document: A comparison of the effect of nitroparacetamol and paracetamol on liver injury.